UroGen Pharma (URGN) Gross Profit Growth (3y) (2020 - 2026)

UroGen Pharma (URGN) Gross Profit Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 54.36%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.16%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 3.86%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.18%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 UroGen Pharma 2.07 Bn 1.93 Bn 46.82 Mn 46.38%

Historic Data

Download Data
DateValue
Mar 31, 2026 46.38%
Dec 31, 2025 29.71%
Sep 30, 2025 19.80%
Jun 30, 2025 11.88%
Mar 31, 2025 14.19%
Dec 31, 2024 14.85%
Sep 30, 2024 31.06%
Jun 30, 2024 19.13%
Mar 31, 2024 37.30%
Dec 31, 2023 42.68%
Sep 30, 2023 80.33%
Jun 30, 2023 286.43%
Jun 30, 2022 835.95%
Sep 30, 2021 147.12%
Jun 30, 2021 531.87%
Mar 31, 2021 405.51%
Dec 31, 2020 467.59%
Sep 30, 2020 -25.15%